Benefit-risk profile of tofacitinib in patients with moderate-to-severe chronic plaque psoriasis: pooled analysis across six clinical trials.

ABSTRACT:

Background

Although existing psoriasis treatments are effective and well tolerated in many patients, there is still a need for new effective targeted treatment options. Tofacitinib is an oral Janus kinase inhibitor that has been investigated in patients with moderate-to-severe chronic plaque psoriasis.

Objectives

To consider the benefits and risks of tofacitinib in patients with moderate-to-severe psoriasis.

Methods

Data were pooled from one phase II, four phase III and one long-term extension study comprising 5204 patient-years of tofacitinib treatment. Efficacy end points included patients achieving Physician's Global Assessments of 'clear' or 'almost clear', ≥ 75% and ≥ 90% reduction in Psoriasis Area and Severity Index (coprimary end points) and improvements in De

SUBMITTER: Strober BE 

PROVIDER: S-EPMC7379291 | biostudies-literature | 2019 Jan

REPOSITORIES: biostudies-literature